Sera Prognostics Reports Q2 2025 Financial Results with Revenue Decline and Increased Operating Losses

Sera Prognostics, Inc. reported its financial results for the second quarter of 2025, revealing a modest revenue of $17,000, a decrease from $24,000 in the same period last year. For the first half of 2025, the company generated $55,000 in revenue, significantly up from $24,000 in the first half of 2024. Despite this increase in revenue, Sera Prognostics continues to face substantial operating losses, reporting a net loss of $8.0 million for the second quarter and $16.2 million for the first half of the year, compared to losses of $8.3 million and $16.4 million, respectively, in the prior year.

The company’s total operating expenses for the second quarter were $9.3 million, slightly higher than the $9.3 million reported in the same quarter of 2024. Research and development expenses decreased to $3.3 million from $4.4 million year-over-year, reflecting a strategic reduction in costs as the company winds down certain clinical studies. In contrast, selling and marketing expenses rose to $1.8 million, up from $1.1 million, as Sera Prognostics expands its commercial efforts, including hiring key personnel to enhance its market presence.

Sera Prognostics has made significant strides in its operational strategy, particularly with the PreTRM test, which is designed to predict the risk of preterm birth. The company has recently published positive results from clinical trials, including the AVERT PRETERM TRIAL, which demonstrated a reduction in neonatal morbidity and mortality. These findings are expected to bolster the adoption of the PreTRM test among healthcare providers and payers. The company is also expanding its commercial team, having appointed a new Chief Commercial Officer and additional sales representatives to drive growth in targeted geographies.

As of June 30, 2025, Sera Prognostics reported total assets of $111.8 million, a significant increase from $72.6 million at the end of 2024, primarily due to the successful completion of a public offering in February 2025 that raised approximately $53.6 million in net proceeds. The company’s cash and cash equivalents stood at $5.0 million, with marketable securities totaling $103.5 million. Looking ahead, Sera Prognostics anticipates continued operating losses as it invests in the commercialization of the PreTRM test and the development of additional diagnostic products. The company believes its current cash runway is sufficient to support operations through 2028, contingent on achieving market adoption and securing payer contracts.